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The 999del5 mutation is the single, strong BRCA2 founder mutation in Iceland and the most common BRCA1/2
founder mutation in Finland. To evaluate the origin and time since spreading of the 999del5 mutation in
Iceland and in Finland, we constructed haplotypes with polymorphic markers within and flanking the BRCA2
gene in a set of 18 Icelandic and 10 Finnish 999del5 breast cancer families. All Icelandic families analysed
shared a common core haplotype of about 1.7 cM. The common ancestors for the Icelandic families studied
were estimated to trace back to 340 – 1000 years, not excluding the possibility that the mutation was brought
to Iceland during the settlement of the country. Analysis of the Finnish families revealed two distinct
haplotypes. A rare one, found in three families in the old settlement region in southwestern Finland, shared a
four-marker (0.5 cM) core haplotype with the Icelandic 999del5 haplotype. A distinct *6 cM haplotype was
shared by seven 999del5 Finnish families estimated to have a common ancestry 140 – 300 years ago. These
families cluster in two geographical regions in Finland, in the very same area as those with the rare haplotype
and also in the most eastern, late settlement region of Finland. The results may indicate a common ancient
origin for the 999del5 mutation in Iceland and in Finland, but distinct mutational events cannot be ruled out.
The surprising finding of the same mutation in two completely different haplotypes in a sparsely populated
area in Finland may suggest gene conversion. European Journal of Human Genetics (2001) 9, 773 – 779.
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Introduction
The two major high-risk breast cancer susceptibility genes,
BRCA1 and BRCA2,1 – 3 have been widely studied in different
populations, and at the Breast Cancer Information Core
database, more than 1700 different mutations have been
reported. Most of the mutations have been reported only
once (about 1100) but several population-specific founder
mutations, as well as founder mutations found in geogra-
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phically diverse populations have been described.4 The
proportion of non-recurrent versus founder BRCA1 and
BRCA2 mutations varies widely among populations, reflect-
ing historical influences of migration, population structure,
and geographic or cultural isolation.
Only one mutation has been identified for each of the
BRCA1 and BRCA2 genes in Icelandic breast cancer families.
In BRCA1, a splice site mutation in exon 17, 5173 G4A, has
been identified in three families sharing a common
haplotype.5 In BRCA2, a 5 bp deletion in exon 93 has been
found in the majority (2/3) of high-risk Icelandic breast
cancer families6,7 and to a lesser extent (1/3) in randomly
selected pairs of sisters diagnosed with breast cancer at the
age of 60 years or younger.8 The population prevalence of this
mutation in Iceland is 0.4%, and among breast cancer or
ovarian cancer patients, 8.5 and 7.9% respectively.9 The
999del5 mutation is also found in 40% of Icelandic male
breast cancer cases.10
So far, more than 20 distinct BRCA1 and BRCA2 mutations
have been found in Finnish families, accounting for about
20% of Finnish breast and breast-ovarian cancer families.11–13
Fourteen of the mutations are founder mutations and
account for the vast majority of all BRCA1/2 families as well
as 1.8% of breast14 and 5.0% of ovarian cancer cases in
Finland.15 Of all BRCA1/2 mutations in Finland, the 999del5
appears to be the most common founder mutation,
accounting for 17% of all BRCA1/2 families and one third
of BRCA2 families.12 In addition to Iceland and Finland, the
BRCA2 999del5 mutation (reported as 995del5) has also been
reported in one family of Puerto Rican origin16 but, as yet, it
has not been reported in the other Nordic countries.
In this study we constructed haplotypes in sets of Icelandic
and Finnish breast and breast-ovarian cancer families with
markers within and flanking the BRCA2 gene to study the
origin and the time since spreading of the 999del5 mutation
i.e. the number of generations since the common ancestors
of the families studied.
Subjects and methods
Kindreds
Eighteen Icelandic and ten Finnish breast and breast-ovarian
ovarian cancer families were included in this study. The
Icelandic breast cancer families were all ascertained at the
University Hospital of Iceland. Pedigree data was obtained
from the Icelandic Genetic Council at the University Hospital
of Iceland and verification of cancer diagnoses from the
Department of Pathology, University Hospital of Iceland, and
at the Icelandic Cancer Registry. Five of the families (2F, 4, 5A/
B,6,and7A/C)were largehighrisk families and13werepairsof
sisters (2, 10, 13, 15, 16, 21, 23, 24, 32, 51, 57, 59, and 67)
diagnosed with breast cancer at the age of 60 years or younger.
The Finnish 999del5 families were ascertained by four
different research groups at the Helsinki, Tampere and Oulu
University Hospitals by mutation screening of breast and
breast-ovarian cancer families. For most of the Finnish
kindreds pedigree data and the birthplaces of parents or
grandparents of the probands were traced using genealogy
registries andchurchparish records asdescribed.17 For families
97, 102 and 113 only the birthplace of the proband was
available. Cancer diagnoses were verified through hospital
records and the Finnish Cancer Registry when possible.
Genotyping
The haplotypes segregating within the five large Icelandic
families were mapped extensively with 28 markers covering
29 cM and sister pairs were typed with 5 of these 28 markers
(Figure 1). Twenty-four markers spanning 36 cM were used in
genotyping of the Finnish families (Figure 3). Primer
sequences published in Couch et al.18 were used for markers
D13S1694, D13S1695, D13S1696, D13S1697, D13S1698,
D13S1699, D13S1701, and those for markers SLS320,
SLS385, SLS165, SLS234, SLS163, SLS312, SLS321, SLS329,
SLS886 were kindly provided by Dr Michael Stratton. Primers
were designed for the intron 11 polymorphism (EX11) at
nucleotide 7069 (+78) and are available on request. All
markers except for EX11 are microsatellite markers. Primer
sequences and genetic distances for the other markers were
obtained from Ge´ne´thon.19
Marker order and physical distances for markers D13S260
through D13S267 were determined by using the genomic
sequence for this region. Genomic sequences were obtained
from The Sanger Centre and marker primer sequences
positioned using Sequencher v3.0 (Gene Codes Corporation,
Ann Arbor, MI, USA). Physical distances were converted to
cM assuming 1 cM=0.5 Mb, which was the average observed
ratio at this region. In a study of recurrent BRCA2 mutations,
Neuhausen et al.20 used between markers D13S290 and
D13S267 an assumption of 1 cM=0.67 Mb, which is similar
to the ratio used in our study.
PCR amplification and genotype scoring of the Icelandic
material was as previously described elsewhere21 Genotyping
of the Finnish families and selected 999del5 mutation
carriers from the Icelandic families for direct comparison of
the allele sizes was carried out with fluorescent technique
using ABI 377 model sequencer (Applied Biosystems, Foster
City, CA, USA). CEPH individual 1347-02 (Coriell Cell
Repositories and Applied Biosystems) was used to ensure
consistent allele calling between individual gels. Genotype
data were analysed using GeneScan v3.1 and Genotyper v2.0
software (Applied Biosystems). For estimating the population
prevalence of the alleles, 96 Finnish population controls and
50 Icelandic controls were genotyped. For estimating the
population prevalence of the core haplotype 14 Icelandic
parents-child control pairs were genotyped.
Haplotype construction and estimation of the time since
the common ancestors of the families
Haplotypes within the families were constructed using
Genehunter (that gives the pattern of inheritance at each
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marker and likely positions of recombinants). The haplotypes
were proofread and some reconstructed by hand due to
Genehunter’s limited capability to assign haplotypes in
pedigrees of complex structure. The history of recombina-
tions in the 999del5-carrying chromosomes between the
families was reconstructed by assuming minimum diversity
of the haplotypes. Starting from the site of the mutation and
moving outward to both directions, historical recombina-
tions were noted as the branching of the haplotype when two
or more different alleles were observed for a marker. The
branched haplotype reconstruction of the Icelandic and the
Finnish families is shown in Figures 1 and 3, respectively.
The number of generations (g) since the common ancestors
of the families studied, denoted as the time since the
spreading of the mutation, was estimated using the Luria-
Delbru¨ck calculation12,22,23 of pexcess=a(17y)
g, where a=1 (all
chromosomes carry the same mutation), and y refers to the
recombination fraction between the mutation and marker
locus. The definition of pexcess was based on the haplotype
reconstructions (Figures 1 and 3). Two modifications of the
calculation12 were used; in one population allele frequencies
were taken into consideration and pexcess was defined as
pexcess=(paffected7pnormal)/(17pnormal) (modification 1)
whereas in the other pexcess was assumed equal to paffected
(modification 2). To achieve the minimum and maximum
estimates for the time since the common ancestors, the
paffected value at each marker was calculated either as the
fraction of haplotypes carrying the allele that was present in
the most common haplotype (minimum estimate) or as one
of the alleles observed in different haplotypes (maximum
estimate). Modification 2 was applied in calculating both the
minimum and maximum estimates, whereas modification 1
was applied only in calculating the minimum estimate and
there pnormal was the frequency of the allele that was present
in the most common mutation haplotype in normal
population chromosomes. The markers for which the genetic
distance from the mutation was known were used for age
estimations (Figures 1 and 3). The average of values obtained
at different markers was considered as the most likely time
estimate.
Results and discussion
This article reports the results of haplotype and genealogical
studies on a large number of breast and breast-ovarian cancer
families in Iceland and in Finland. The results of the
haplotype analysis show that all the Icelandic families share
a common core BRCA2 999del5 haplotype whereas in
Finland two distinct haplotypes are associated with this
mutation.
Haplotype and genealogy studies of Icelandic BRCA2
999del5 families
One common core haplotype was found to segregate within
all the Icelandic families analysed, indicating identity by
descent of the mutation carrier families. The shared
haplotype covered the chromosome region of markers
SLS312 through SLS886 (Figure 1) which is about 0.85 Mb
or approximately 1.7 cM according to the physical distance
of the markers and observed recombination fraction in this
region. The modification 1 of the Luria-Delbru¨ck equation
yielded an estimation of 25 generations or 500 – 625 years
(assuming 20 – 25 years per generation) since the common
ancestor of the families, while the modification 2 used in
estimating both the minimum and maximum time since the
common ancestor gave the range of 16 – 40 generations or
320 – 1000 years.
It is believed that Iceland was settled mainly by Vikings
from western Scandinavia and the British Isles between the
years 860 – 1060.24 – 27 This is supported by studies on
mitochondria DNA and the Y chromosome indicating that
the settlers of Iceland were mainly people of Scandinavian
and Celtic origin.28 – 30 The finding of only two BRCA1/2
mutations in Iceland and both shown to be founder
mutations probably reflects the demographic history of
subsequent drastic and repeated population bottlenecks,
which is likely to have reduced the genetic diversity
introduced by the original settlers.
Nine variants of the haplotype could be identified in 16 of
the families as shown in Figure 1, where the 999del5 families
have been given different symbols based on sharing of the
haplotype between markers D13S220 and D13S1246. In two
families the haplotype variant was uncertain due to lack of
information on markers centromeric to the 999del5 muta-
tion. Locating the families on the map of Iceland according
to the birthplaces of the grandparents shows that the
different haplotype variants tend to cluster in different
regions of the country (Figure 2), despite the rather even
distribution of Icelandic inhabitants on the coastal regions
around the country at the end of the 19th century and
beginning of the 20th century. Genetic drift is likely to be
responsible for the difference in the frequency of the 999del5
haplotype variants and the clustering of these variants in
different parts of the country.
Haplotype and genealogy studies of Finnish BRCA2
999del5 families
In Finland, two different haplotypes were observed in the
999del5 families (Figure 3). A rarer haplotype (denoted as
haplotype A) was present in three families, and a more
common haplotype (denoted as haplotype B) was present in
seven families. The number of families sharing the rare
haplotype A is too low for time estimation. All three families
share a haplotype covering 16 markers from marker D13S260
telomeric to marker D13S267 (approximately 3 cM) with the
exception of marker D13S1698. At this marker allele 1 is
found to segregate with the mutation in family 158 and allele
2 in families 6003 and 102. This difference in allele sizes in
the middle of an otherwise shared haplotype is probably due
to a mutation31 or a null allele.32
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Haplotype A shares allele sizes also with the Icelandic
haplotype at three markers (SLS329, D13S1697, D13S163) in
two families and in one family also at the fourth marker
(D13S1698) adjacent to the mutation spanning about 200 kb
or approximately 0.5 cM. The estimated frequency of this
haplotype in normal chromosomes is about 1.3%
Figure 1 The branched haplotype reconstruction of the Icelandic families, revealing the minimum number of historical recombinations.
The order of markers and their relative distances from the 999del5 mutation in cM are shown on the top of the figure. The five markers
that were used in genotyping sister pairs are indicated with *. The markers that were used for age estimations span 29 cM around the
BRCA2 gene and are marked with italics. Family members are indicated after a colon in case of recombination within families. The
haplotype variants found to segregate in the families have been marked with different symbols according to the extent of sharing a
common haplotype between the markers D13S220 and D13S1246 (marked with bold). A four-marker haplotype 1-1-1-1 (indicated with
bold) at markers D13S1698-SLS163-D13S1697-SLS329 is present in the Icelandic core haplotype and in the Finnish haplotype A.
.=unknown allele.
Figure 2 Schematic drawing of Iceland showing geographical
distribution of the birthplaces of the grandparents of the
proband of each of the 18 Icelandic families analysed (two
symbols for each family). The nine haplotype variants are
represented by distinct symbols (see the text for Figure 1).
Figure 3 Haplotype reconstruction A of the three Finnish
families and B of the seven Finnish families. The order of the
markers studied and their relative distances in cM are shown on
the top of the figure. The markers that were used for age
estimations span 36 cM around the BRCA2 gene and are marked
with Italics. A four-marker haplotype 1-1-1-1 (indicated with
bold) at markers D13S1698-SLS163-D13S1697-SLS329 is
shared between the Icelandic families and the Finnish families
with haplotype A.
BRCA2 breast cancer families
RB Barkardottir et al
776
European Journal of Human Genetics
(0.8260.1860.3760.24) in the Finnish population and
2.2% (0.8260.2260.5360.23) in the Icelandic population,
assuming equilibrium between markers. The actual fre-
quency of a two-marker haplotype available (allele 1 at
D13S1698 and allele 1 at D13S1697, estimated frequency
4.3%)12 was 2% in 102 normal chromosomes in Finland and
for a three marker haplotype (allele 1 at D13S1698, allele 1 at
SLS163 and allele 1 at SLS329, estimated frequency 10.0%) in
Icelandic controls (28 chromosomes) it was 3.6%. Thus, a
coincidence of similar short haplotypes in the Icelandic and
Finnish families cannot be ruled out. On the other hand, if
these haplotypes are identical by descent and there is only
one mutational event then the common origin must be
significantly older than the Icelandic haplotype expansion.
The seven Finnish families segregating haplotype B all
share a common region covering markers D13S1246 through
D13S1696 and spanning approximately 6 cM (Figure 3).
Time estimation since the common ancestry of these families
using the modification 1 of the Luria-Delbru¨ck equation was
eight generations or 160 – 200 years whereas using the
modification 2 it was 7 – 12 generations or 140 – 300 years.
Tracing the origin of the grandparents of the 10 Finnish
999del5 families revealed that the families form two clusters
in geographically distinct regions in Finland. The families
carrying haplotype A have their origins in the old agricultural
area in Pirkanmaa, belonging to the early settlement region
in the southwest of Finland (Figure 4). The families
segregating haplotype B originate from two distinct geogra-
phical regions: from the very same small region in Pirkanmaa
as the families segregating haplotype A, and from the new
settlement region in the most eastern part of the country
(Figure 4). Finland is likely to have been inhabited
continuously since the last glacial period about 9000 years
ago by small groups mainly from the south and east, but also
from the west.33 For centuries, only the coastal regions of the
south, southwest, and southeast (old settlement region) were
permanently inhabited. An internal migration towards the
central and northern parts of the country (new settlement
region) began only in the 16th century and resulted in rural
subisolates whose major population expansion began in the
17th century.34
The presence of two distinct 999del5 haplotypes in the
Finnish population is quite surprising, and even more so as
families carrying both haplotypes cluster in the very same
small area in the old settlement region. It is possible that the
999del5 region of the BRCA2 gene represents a mutational
hotspot and the two distinct haplotypes in Finland represent
different mutational events as well as the one in Iceland and
the 999del5 mutation in a family of Puerto Rican Hispanic
ancestry. It has been proposed that short symmetric elements
predispose DNA sequences to meiotic microdeletion35 and
indeed, partially overlapping and closely flanking the 999del5
mutation three symmetric elements can be identified.
However, another possible explanation for two haplotypes
in Finland is a gene conversion. Both haplotypes A and B are
present in a very small geographical region, in adjacent
communities in an old sparsely populated region and
haplotype B also in a more recently inhabited region.
Interestingly, a similar situation has been observed in
autosomal recessive congenital ichtyosis: an identical trans-
glutaminase 1 gene (TGM1) mutation is present in two
haplotypes in the Savo region in southeastern Finland, and
one of the haplotypes is also present in central Finland36 that
was inhabited in the 16th century mainly by population
movement from South Savo.37
Figure 4 Map of Finland showing the geographical
distribution of the ancestry of the 999del5 families. The circles
indicate origins of the families carrying the haplotype A and the
squares indicate origins of the families carrying the haplotype B.
The small symbols represent birthplaces of the earliest known
cancer generation (two symbols for each family) and the large
symbols birthplaces of the proband, if information of the
previous generations was not available.
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Thus, an alternative theory for a mutational hotspot and
independent mutational events could be an ancient com-
mon origin for the Icelandic and Finnish 999del5 mutations.
The ancient 999del5 mutation could have been introduced to
both Iceland and Finland during different time periods. The
short common core haplotype seen in the present day
families in Iceland and in Finland, as well as the absence of
the mutation in other populations studied, may reflect
extinction of ancient branches in populations with repeated
bottlenecks. In Finland, the haplotype A in the old
settlement region may be the original one from which
haplotype B may have diverged by gene conversion.
Individuals carrying the new haplotype may have migrated
to the east of Finland during the more recent settlement of
this part of the country, forming a regional cluster there.
Although this theory remains unproven, it would be in
agreement with the population historical records.
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